Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer

Inclusion Criteria: * Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) * Locally advanced stage IIIA or IIIB disease that is considered unresectable * No stage IV disease * Requires radiotherapy * Performance status (PS) - Eastern Cooperative Oncology Group (ECOG) 0-1 * At least 12 weeks * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Bilirubin ≤ 1.5 times upper limit of normal (ULN) * aspartate aminotransferase (AST) ≤ 3 times ULN * Creatinine ≤ 1.5 times ULN * No New York Heart Association class III or IV heart disease * Forced expiratory volume (FEV) FEV\_1 ≥ 1 L OR 35% of predicted * Weight loss \< 10% within the past 3 months * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No peripheral neuropathy ≥ grade 2 * No other severe underlying disease that would preclude study participation * No uncontrolled infection * No unhealed wound within the past 2 weeks * No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, adequately treated noninvasive carcinomas (carcinoma in situ), or localized prostate cancer * No concurrent prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF) * No prior systemic chemotherapy for NSCLC\* * No prior radiotherapy to the chest * More than 2 weeks since prior major surgery Contraindications * Any of the following: * Pregnant wome * Nursing women * Men or women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device \[IUD\], or abstinence, etc.) as this regimen may be harmful to a developing fetus or nursing child NOTE: This study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. * Any of the following prior therapies: * Prior radiation therapy to the chest * Prior systemic chemotherapy for NSCLC (phase II portion) * New York Heart Association classification III or IV (see Appendix II). * Any other severe underlying diseases which are, in the judgment of the investigator, inappropriate for entry into this study. * uncontrolled infection. * Major surgery or unhealed wound ≤ 2 weeks prior to registration. * Prior history of malignancy ≤ 5 years, except for adequately treated basal cell or squamous cell skin cancer, adequately treated noninvasive carcinomas (carcinoma in situ), or localized prostate cancer. * Peripheral neuropathy ≥grade 2